TickerTalks
Browse all tickers →
TickerTalks›$OPRX
OPOPRX

OptimizeRx Corp.

$OPRX·$137M·Medical - Healthcare Information Services·Healthcare
$8.55+1.9%YTD-32.2%1Y-55.8%
Price updated just now·X counts updated 5d ago
OPOPRX
$OPRXOptimizeRx Corp.
$8.55+1.89%44 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $OPRX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

44X posts · last 7 days
Sep 14Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $OPRX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $OPRX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storyWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

OptimizeRx is down 32% YTD on contracting revenue — Nov 5 earnings tests whether the pharma-marketing book stabilizes.

OptimizeRx is a point-of-care digital health company — connects pharmaceutical marketing content to electronic health record workflows. The business has been in a continued revenue reset.

  • The business is contracting: Q1 revenue -30% YoY at a slightly-positive operating margin — top-line declining meaningfully as pharma marketing budgets reset, with PE 36x reflecting weak TTM earnings.
  • At PS 1.67x the valuation is reasonable for a struggling specialty-tech but has downside if revenue continues to decline — the market is pricing in a bottoming attempt rather than a confirmed turn.
  • 52-week range position is 22% with volume at 119% of average — lower-mid range on above-average volume, which is often how a bottoming attempt forms before a confirmed turn.

Nov 5 Q3 is the gate — any revenue stabilization plus confirmed pharma-marketing contract renewals extends the stock off the floor. Another revenue decline or margin compression and the stock stays range-bound.

What to watch: Nov 5 Q3 — revenue trajectory, pharma-marketing bookings, operating-margin direction, and FY27 guide. Another revenue decline is the clear invalidator.

On the calendar: 2026-11-05 — Q3 earnings

Read the AI verdict on $OPRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Digital health platform delivering pharma brand messaging to physicians through integrated EHR workflows at the point of prescribing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $OPRX.

Medical - Healthcare Information Services · Healthcare

No material change from last week — AI-driven clinical workflow digitization and prior-authorization automation are the structural demand drivers.

What this means for $OPRX

Partial — Digital health platform delivering pharma brand messaging to physicians through integrated EHR workflows at the point of prescribing.

Industry benchmark

10-name peer basket
+23.0%YTD
+15.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
36.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
4.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
11.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
11.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
3.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
72.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$0.16$0.11+44.0%
Q1 2026May 12, 2026$0.14$0.01+1300.0%
Q4 2025Mar 5, 2026$0.51$0.23+121.7%
Q3 2025Nov 6, 2025$0.20$0.03+566.7%
Next earningsThu, Nov 5·consensus EPS $0.19

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$20.5M-29.8%76.5%-0.4%$-0.04$8.6M
Q1 FY26$19.8M-9.5%69.9%2.0%$-0.03$-488K
Q4 FY25$32.2M-0.2%74.8%27.7%$0.27$7.1M
Q3 FY25$26.1M+22.3%67.2%7.9%$0.04$3.2M

Forward consensus

2-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$96.6M$95.5M – $97.3M$0.91$0.87 – $0.955
FY27$107.6M$101.7M – $117.0M$1.10$0.98 – $1.295

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.22%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 14.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 19 other (11 awards · 8 inkinds) in window

See when $OPRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 128-K — Item 2.02: Earnings release · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

OptimizeRx Corporation reported Q2 2026 financial results and announced a planned CFO succession: Edward Stelmakh will step down as Chief Financial and Strategy Officer on December 31, 2026, with Andrew D'Silva taking over as CFO and Heather Favazza becoming Chief Accounting Officer on January 1, 2027. Stelmakh's separation package includes 12 months of salary continuation at his $450,000 annual rate, a $247,500 lump-sum bonus, and COBRA reimbursement. OptimizeRx operates a digital health platform connecting pharmaceutical companies with healthcare providers. The orderly transition plan provides over five months of overlap.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
8-KOfficer or director changeJun 58-K — Item 5.02: Officer or director change
8-KAgreement terminatedMay 128-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.02: Earnings release · Item 2.03: Material debt obligation
3New insider — initial holdingsApr 223
8-KOfficer or director changeApr 98-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 9 other (3 13Gs · 2 10-Qs · 2 proxys · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?zacks.com·9d agoOptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPathglobenewswire.com·10d agoOptimizeRx: Gross Margin Gains And Improved Long-Term Outlookseekingalpha.com·14d agoReviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)defenseworld.net·17d agoOptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligenceglobenewswire.com·18d ago

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$HCAT$DOCS$TDOC$SOPH$HNGE$BTSG$HTFL
Voices on X · last 7 days

No standout posts about $OPRX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport